{"id":"W3089254712","doi":"10.1016/j.ygyno.2020.09.006","title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Université de Sherbrooke","funders":"Genentech; Medac; Eisai; Merck KGaA; Clovis Oncology; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Takeda Oncology; Amgen; Pfizer; PharmaMar; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Placebo; Ovarian cancer; Oncology; Internal medicine; Nova (rocket); Term (time); Gynecology; Cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000399048,0.0003962374,0.0009403873,0.00008257966,0.0001472408,0.00002016502,0.0002806647,0.0003664772,0.001934354],"category_scores_gemma":[0.0004482063,0.000235556,0.00008598138,0.0006315717,0.0003401601,0.00009194599,0.00006834948,0.0007917769,0.00004395897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001400089,"about_ca_system_score_gemma":0.0009871363,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005496535,"about_ca_topic_score_gemma":0.004722218,"domain_scores_codex":[0.9968359,0.0005283921,0.0008107406,0.0008482349,0.0004002416,0.0005764917],"domain_scores_gemma":[0.9967304,0.001790997,0.0005269957,0.0004872681,0.000196169,0.0002681339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8929302,0.001886496,0.05278011,0.000009033079,0.000425346,0.0002472392,0.001314929,0.0000719762,0.00004045326,0.00001985015,0.003608525,0.04666583],"study_design_scores_gemma":[0.7387066,0.03946495,0.2035885,0.0001000043,0.0003213662,0.000002811193,0.0001459739,0.00005918251,0.0001231692,0.000006613291,0.01717303,0.0003077695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781489,0.0001395185,0.00005997878,0.01171295,0.001183024,0.003904647,0.0004999311,0.0001320114,0.00421904],"genre_scores_gemma":[0.9938486,0.0001615333,0.0002750137,0.003364078,0.0006964126,0.0005305002,0.001021473,0.00003888419,0.00006350031],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1542235,"threshold_uncertainty_score":0.998978,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06628635318853937,"score_gpt":0.3559843716562436,"score_spread":0.2896980184677043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}